AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
| Revenue (TTM) | $266.93M |
| Gross Profit (TTM) | $198.00M |
| EBITDA | $-6.96M |
| Operating Margin | 1.26% |
| Return on Equity | -10.30% |
| Return on Assets | -2.25% |
| Revenue/Share (TTM) | $5.16 |
| Book Value | $8.31 |
| Price-to-Book | 5.86 |
| Price-to-Sales (TTM) | 11.19 |
| EV/Revenue | 9.67 |
| EV/EBITDA | 79.43 |
| Quarterly Earnings Growth (YoY) | 300.00% |
| Quarterly Revenue Growth (YoY) | 26.20% |
| Shares Outstanding | $59.73M |
| Float | $54.60M |
| % Insiders | 1.94% |
| % Institutions | 96.24% |
Volatility is currently expanding
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?
ALACHUA, Fla. and TAMPA, Fla.
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ALACHUA, Fla. and TAMPA, Fla.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXGN and any ticker you trade — then tracks every position and per-strategy win rate.
